Maxim Group analyst Allen Klee reiterated a Buy rating on Marpai (MRAI – Research Report) yesterday and set a price target of $3.00. The company’s shares closed yesterday at $0.98.
According to TipRanks, Klee is an analyst with an average return of -22.6% and a 24.16% success rate. Klee covers the Technology sector, focusing on stocks such as CareCloud, Research Solutions, and Marpai.
Marpai has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
Based on Marpai’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4.94 million and a GAAP net loss of $5.78 million. In comparison, last year the company earned a revenue of $4.8 million and had a GAAP net loss of $4.79 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marpai Inc operates as a health plan company. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees.
Read More on MRAI:
